why choose us

First received: May 17, 2023

Clinical Trial: LINNOVATE: Lurbinectedin, Ipilimumab and Nivolumab for Soft Tissue Sarcoma

Study Status: Completed

Recruit Status: RECRUITING

Condition: Advanced Soft-tissue Sarcoma

Study Type: INTERVENTIONAL


Official Title: LINNOVATE: A Phase 1/2 Study of Safety/Efficacy Using LURBINECTEDIN, Combined With IPILIMUMAB, and NIVOLUMAB for Advanced Soft Tissue Sarcomas

Brief Summary: This is an open label, dose-seeking phase 1/2 study using escalating doses of LURBINECTEDIN administered intravenously with fixed doses of IPILIMUMAB and NIVOLUMAB administered intravenously.

Read more